When Inex Pharmaceuticals Corp. acquired a portfolio of antisense therapeutics, patents and manufacturing facilities from Lynx Therapeutics Inc. in 1998, the primary driver was therapeutics. But the acquisition now has an added perk for Inex (TSE:IEX), which believes it has developed a new delivery platform, OligoVax, for use in treating cancer and infectious diseases.

OligoVax involves encapsulating immunostimulatory phosphodiester oligonucleotides - those containing a CpG sequence - in a lipid envelope. The oligos target antigen presenting cells, thereby inducing an immune response.